Effect of External Counterpulsation (ECP) on Delayed Onset Muscle Soreness (DOMS) in Long Distance Runners by Catanese, Carly
Cleveland State University
EngagedScholarship@CSU
ETD Archive
2007
Effect of External Counterpulsation (ECP) on
Delayed Onset Muscle Soreness (DOMS) in Long
Distance Runners
Carly Catanese
Cleveland State University
Follow this and additional works at: https://engagedscholarship.csuohio.edu/etdarchive
Part of the Medicine and Health Sciences Commons
How does access to this work benefit you? Let us know!
This Thesis is brought to you for free and open access by EngagedScholarship@CSU. It has been accepted for inclusion in ETD Archive by an
authorized administrator of EngagedScholarship@CSU. For more information, please contact library.es@csuohio.edu.
Recommended Citation
Catanese, Carly, "Effect of External Counterpulsation (ECP) on Delayed Onset Muscle Soreness (DOMS) in Long Distance Runners"
(2007). ETD Archive. 722.
https://engagedscholarship.csuohio.edu/etdarchive/722
  
EFFECT OF EXTERNAL COUNTERPULSATION (ECP) ON DELAYED ONSET 
MUSCLE SORENESS (DOMS) IN LONG DISTANCE RUNNERS 
 
CARLY R. CATANESE 
 
Bachelors of Science in Communication 
Ohio University 
JUNE 2006 
 
 
 
Submitted in partial fulfillment of requirements for the degree 
MASTER OF EDUCATION IN EXERCISE SCIENCE 
At 
CLEVELAND STATE UNIVERSITY 
DECEMBER 2007 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
©Copyright by Carly Rae Catanese 2007 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
ACKNOWLEDGEMENTS 
 
I would like to thank the following individuals for their assistance and encouragement 
with my thesis: 
Anthony, Lynette, Tana, and Shana Catanese, family, and friends 
Louis Keppler, M.D. and his staff at Saint Charity Hospital 
Kathleen Little, Ph. D 
Codruta Rafiroiu, Ph. D 
Kenneth Sparks, Ph. D 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
This thesis has been approved for the Department of HEALTH, PHYSICAL 
EDUCATION, RECREATION, AND DANCE and the College of Graduates Studies 
by 
 
 
___________________________________ 
Thesis Committee Chairperson, Dr. Kenneth Sparks 
 
___________________________________ 
Department/Date 
 
____________________________________ 
Dr. Kathleen Little 
 
____________________________________ 
Department/Date 
 
____________________________________ 
Dr. Codruta Rafiriou 
 
_____________________________________ 
Department/Date
 v 
 
EFFECT OF EXTERNAL COUNTERPULSATION (ECP) ON DELAYED ONSET 
MUSCLE SORENESS (DOMS) IN LONG DISTANCE RUNNERS 
 
CARLY RAE CATANESE 
 
ABSTRACT 
External counterpulsation (ECP) has previously been used in treating cardiac patients.  
Compression of the lower extremities during diastole increases venous return and 
coronary perfusion.  
Purpose:  To determine if ECP affects delayed onset muscle soreness (DOMS) and 
markers of muscle inflammation and skeletal muscle damage. 
Methods:  Ten trained runners, 5 males and 5 females, aged 30.5 ± 12.8 years ran 20 
miles at 70% of their VO2 max on a pre-determined course on two different occasions, 
once under control conditions and once under ECP treatment conditions.  Conditions 
were randomly assigned to eliminate order effect. Perceived leg pain and blood markers 
(creatine kinase, CK; lactate dehydrogenase, LDH; and C-reactive protein, CRP were 
measured pre-run, immediate post-run and for 5 consecutive days post-control and ECP 
treatment runs.  During the treatment condition, subjects received 60 minutes of ECP 
post-run and everyday for 5 days post-run.  To control for effects of ECP 5 additional 
subjects aged 25.6 ± 2.1 years received 5 days of ECP treatment while remaining 
inactive.  Repeated measures ANOVA was used to assess treatment effects.  Protected    
t-tests were used to assess serial differences.  Correlations were obtained to assess 
 vi 
 
relationships between dependent variables.  Repeated measures ANOVA were also used 
to assess gender differences in the control run and treatment run. 
Results: There was no significant difference in mean weight loss, fluid intake, exercise 
heart rate, percentage of maximum heart rate or maximal oxygen consumption (VO2) 
achieved, or running time between the control and ECP treatment runs.  All indicators of 
muscle damage (CK, LDH, CRP, and pain) increased over time for the two runs, 
although there were no significant changes in the control group receiving ECP treatment 
only.  CRP, pain, and LDH significantly decreased by two, one, and one day(s) post-ECP 
treatment, respectively, compared to the control condition.  CK remained significantly 
elevated longer (3 days) in the ECP treatment run group.  Positive correlations were 
found between CRP and CK (Day 3, 4, and 5), DOMS and LDH (immediately post-run), 
DOMS and CRP (Day 2), and CK and LDH (Day 5) in the control run only.  Only 
females experienced a significant difference in CRP and CK, a 20% increase in CRP and 
a significant difference in CK immediately post-runs.  A 20% reduction in pain was 
observed for both males and females as a result of treatment, though females experienced 
pain for one additional day.  Females experienced a 20% increase in LDH.  Males 
experienced a significant change Day 4 of the control run and immediately post-ECP 
treatment run, though difference between LDH significance may be attributed to the 
subject variability response.  
Conclusions: ECP treatment after prolonged running decreased inflammation, muscle 
pain, and LDH elevation.  CK levels remained elevated significantly in the ECP 
treatment run when compared to the control run.  ECP alone did not cause significant 
increases in CK suggesting other factors contributed to this.  Relationships exist between 
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indicators of muscle damage and inflammation.  Gender differences were found in 
response to the ECP treatment run and control run. 
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CHAPTER I 
INTRODUCTION 
Background 
Enhanced external counterpulsation (EECP*) was originally designed as a mode 
of treatment for people diagnosed with coronary artery disease (CAD).  While Europeans 
have used it for treatment for many years, not until recently did the United States use it 
for the purpose of treating cardiac patients.  EECP has been mainly used for patients 
experiencing angina.  The purpose of EECP is to increase perfusion of blood through the 
heart, therefore increasing oxygen supply to the myocardium.  It has been documented 
that ECP* treatments over time increases the growth of collateral blood vessels.
1 
 These 
collateral vessels provide a means of greater oxygen supply to the myocardium. 
ECP uses pneumatic compression cuffs that are placed on a patient’s calves, 
thighs, and buttocks, increasing blood flow to the heart.  Inflation of the cuffs increases 
blood flow to the heart.  This causes a change in blood volume and pressure in the aorta 
during diastole, which increases perfusion of the coronary arteries.  When the 
compression cuffs deflate, it results in blood flowing back through the buttocks, thighs, 
  2 
and calves, normalizing aortic cavity pressure.
1
  The timing of the deflation in the early 
phase of systole can cause a reduction in pressure and workload of the heart.  Therefore, 
less cardiac work lowers the oxygen demand.
1,2
 
According to Wilmer et al.
3
, EECP treatment allowed patients to increase their 
tolerance for exercise as a result of increased blood flow, which helped to improve the 
quality of their lives.  Patients had experienced less fatigue during daily routine activities 
and increased their activity level and duration of those activities.
2 
  
Previous research conducted on myocardial muscle damage
3
 and on skeletal 
muscle damage from long distance running,
4
 have entertained the idea that myocardial 
and skeletal muscle damage are not all that different.  Lezhen
5
 found that athletes treated 
with ECP increased lactic acid clearance of the blood and recovery from high intensity 
exercise.  This was likely due to increased venous return from the lower extremities.                        
 
            Delayed onset of muscle soreness (DOMS) is an effect of  performing an exercise 
that the body is not accustomed to or that places a great deal of strain on the skeletal 
muscles, especially subsequent eccentric exercise.
6 
  McArdle and Katch
7
 have proposed 
a DOMS Model which includes a series of events occurring from DOMS to recovery.  It 
is proposed that DOMS causes damage to the sarcolemma, the muscle cell membrane.  
This damage results in the release of biochemical markers of muscle damage (e.g. 
creatine kinase (CK), lactate dehydrogenase (LDH), and myoglobin (Mb)).  
Unaccustomed exercise can also cause damage to the sarcoplasmic reticulum, the primary 
regulator of calcium, an essential metabolite for muscle contraction.  Neural stimulation 
causes intracellular calcium to be released, allowing for muscle contraction.  When neural 
stimulation ceases, muscle action is inhibited as calcium returns for storage in the 
  3 
sarcoplasmic reticulum.  When structure and function of the sarcoplasmic reticulum are 
influenced by unaccustomed exercise it can result in inefficient calcium release and 
absorption and an increased concentration of free moving calcium into the damaged 
muscle fibers.  The free floating calcium in the damaged muscle fibers causes a decreased 
ability to exert force, increased cell damage, therefore, causing inefficient muscle action 
resulting in muscle soreness.  The inflammation process begins as a precursor to full 
recovery of damaged muscle fibers.  Inflammation, indicated by blood marker C-reactive 
protein (CRP), denotes the onset of the healing process.
7 
 It is theorized that if ECP increases blood flow in cardiac patients and aids in 
recovery from high intense exercise it could have an effect on DOMS by increasing 
venous return and skeletal muscle perfusion.  
Statement of the Problem 
Research is needed to determine if ECP might be effective in reducing delayed 
onset of muscle soreness (DOMS) in long distance runners.  
Purpose of the Study 
The purpose of this study was to measure recovery from prolonged running with 
the use of ECP and its effect on reducing DOMS and biochemical markers of muscle 
damage. 
Hypothesis 
1. ECP treatment will reduce the delayed onset of muscle soreness (DOMS). 
2. ECP treatment will reduce biochemical markers of muscle damage (C-reactive 
protein (CRP), creatine kinase (CK), and lactate dehydrogenase (LDH)). 
  4 
3. There will be no difference between genders in response to the ECP treatment run 
and control run. 
Definition of Terms 
For the purpose of this study, several frequently used terms have been defined as 
follows
1
: 
*Different manufacturers use different abbreviations; ECP (external counterpulsation) 
and EECP (enhanced external counterpulsation) are basically the same.  For this 
study, ECP equipment from ScottCare Corporation (Cleveland, OH) was used. 
 DOMS:  Delayed onset muscle soreness or pain is experienced post-exercise due 
to skeletal muscle damage. 
 Diastolic Augmentation:  Diastolic pressure exceeds systolic pressure with a 
peak-to-peak ratio equal to 1.2 or greater, with 1.2 being therapeutic.   
 Peak-to-peak ratio:  The diastolic to systolic ratio (D/S).   
 End-diastolic pressure (EDP): synonymous with preload.  An increase in venous 
return causes an increase in EDP and ventricular filling during the heart’s 
relaxation phase (diastole), which allows more blood to return to the heart during 
the contraction phase (systole). 
 Control run: pertained to the ten subjects who ran 20 miles without ECP 
treatment. 
  ECP treatment run:  pertained to the ten subjects who ran 20 miles followed by 5 
days of ECP treatment. 
  5 
 ECP alone: pertains to 5 additional subjects, different from those involved in the 
two 20 mile runs, who received 5 days of ECP treatment only while remaining 
inactive. 
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CHAPTER II 
LITERATURE REVIEW 
The purpose of this study was to measure recovery from prolonged running with 
the use of ECP and its effect on reducing delayed onset of muscle soreness (DOMS).  
Literature relative to this study and its findings are summarized in the areas of EECP 
treatment and CAD, effect of various modes of exercise on muscle soreness and serum 
markers of DOMS, relationship of DOMS to inflammation, relationship between 
dehydration and DOMS, effect of ECP on recovery after prolonged exercise, and male 
and female responses to exercise induced muscle damage. 
ECP and Cardiovascular Disease 
According to Wilmer et al.,
3
 coronary artery disease, myocardial ischemia, and 
refractory angina go hand-in-hand with arterial stiffness.  Decreasing the elasticity of the 
arteries causes increased strain and pressure on the heart to work harder.  Twenty 
patients, (16 men, 4 women) aged 48 to 70 years, served as subjects for this study.  All 
patients exhibited cardiovascular risk factors, experienced prior cardiac problems and 
  7 
treatments, and had chronic angina for at least 3 months due to myocardial ischemia.  
Drugs and medical procedures could not control the patients’ problems and therefore they 
were prescribed EECP.   
Each patient experienced 35, 1 hour daily EECP treatments for 7-8 weeks with an 
inflation pressure of 200-300 mmHg.  Systolic, diastolic, and pulse pressure were 
measured during each treatment.  Characteristics of the arterial walls and wave 
reflections were monitored and analyzed to determine if treatment improved these 
variables because both influence left ventricle afterload and myocardial oxygen demand.    
Peripheral and central blood pressure, systolic blood pressure, pulse pressure, 
mean and diastolic pressure, and unaugmented pressure significantly decreased.  As a 
result of EECP treatment, arterial stiffness was reduced and less energy was expended by 
the patients.  Therefore, patients were able to increase their tolerance for exercise due to 
increased blood flow, which helped improve the quality of their lives.  Patients 
experienced less fatigue doing daily routine activities and for that reason, they were able 
to increase their activity level and duration of those activities. 
Urano et al.
8
 demonstrated that ECP improved exercise tolerance, reduced 
exercise-induced myocardial ischemia, and improved diastolic filling in patients with 
CAD.  Nine male and 3 female subjects, aged 51 to 78 years, participated in this study.  
All had CAD and documented ischemia, eight with effort angina and four with silent 
myocardial ischemia.   
Each patient experienced sedentary or mild activity in a hospital setting, once 
with EECP treatment and once without.  Before the subjects engaged in any activity, each 
subject had a medical history evaluation, a physical examination, and a stress test.  
  8 
Systolic blood pressure was measured during each minute of rest, during exercise, and 
the first five minutes of the recovery phase.  As soon as the subjects experienced any 
discomfort, such as fatigue or ischemia, exercise was terminated.  The first phase, 
without EECP treatment, lasted 38 ± 9 days.  Each patient underwent 35 hours of EECP 
treatment, each session lasting one hour, which was performed once or twice daily.  This 
phase lasted 36 ± 6 days.  Clinical examinations were performed before and after EECP 
treatment. 
Cuffs were wrapped around the subjects’ legs which exerted a pressure of        
300 mmHg on the lower extremities in accordance with the subject’s cardiac cycles.  The 
results of the EECP treatment were determined by calculating the mean diastolic to 
systolic pressure ratio.  From treatment, the mean diastolic to systolic pressure ratio was 
1.1 ± 0.4 indicating that diastolic augmentation was achieved. 
Exercise duration and exercise tolerance both significantly improved after EECP 
treatment.  The results also showed that EECP treatment increased myocardial perfusion.  
There was a decrease in ―the prevalence of reversible perfusion defects‖ and an increase 
in ―the prevalence of normal perfusion‖ (p.96).  It was concluded that exercise tolerance 
improved due to reduced episodes of myocardial ischemia. 
Masuda et al.
9
 found that ECP improved myocardial perfusion at rest as well as 
increased exercise tolerance and suggested that EECP treatment increased the production 
and use of collateral vessels.  Eleven subjects, aged 21 to 81 years, who had been 
diagnosed with chronic stable angina participated in this study.  They all performed a 
treadmill test, N-ammonia positron emission tomography, and had blood drawn within 
four weeks prior to treatment.  The cuffs were placed on the calves, thighs and buttocks 
  9 
and pressure was applied at the beginning of diastole.  Once diastole had ended the 
pressure was released by deflating the cuffs.  The amount of pressure used in this study 
was 250 mmHg and the treatment amounted to 35 hours, one to two sessions daily, taking 
approximately eighteen to thirty-five days.   
The results revealed that myocardial perfusion at rest and perfusion in the anterior 
walls increased.  There was also an increase in coronary flow reserve (maximal flow 
capacity) and exercise tolerance; however the latter was not significant. 
The Effect of Various Modes of Exercise on DOMS and Serum Markers of Skeletal 
Muscle Damage 
Schwane et al.
10
 were the first researchers to study how running at different 
grades influence muscle soreness.  They hypothesized that running down an incline, in 
which muscles are experiencing eccentric contractions, caused greater DOMS than 
running on level ground.  Seven male subjects, aged 19 to 21 years, volunteered for this 
study.  All were physically active on a regular basis, but for the duration of the study 
were asked to abstain from activity other than that performed during the experiment.  
Each subject performed three treadmill tests: a maximal oxygen consumption (VO2 max) 
test, a run on level ground (0% grade), and a run at a 10% grade downhill, both for a 45 
minute duration.  
 DOMS was assessed via plasma levels of creatine phosphokinase (CPK) and 
lactate dehydrogenase (LDH) before exercise, 5 minutes, 24, 48, and 72 hours after the 
run at each grade.  Subsequent tests were not performed immediately after the first.  Six 
of the subjects waited six to seven days, and the seventh subject waited twenty-three days 
  10 
between test one and two, and fourteen days between test two and three.  Muscle soreness 
was also assessed using the Abraham scale. 
 There was significant muscle soreness in the gluteal, quadriceps, anterior leg, and 
posterior leg muscles, but not the hamstrings after the downhill run, while there was no 
significant muscle soreness after the run on level ground.  There was no significant 
change in LDH levels, but there was a 351% increase of CPK within 24 hours of running 
downhill.  The researchers also wanted to determine if there was a relationship between 
DOMS and inflammation, identifiable by the abundance of white blood cells found in the 
blood, but no significant relationship was found.   
According to their results, Schwane et al.
10
 found that running downhill 
perpetuated muscle soreness and caused CPK levels to significantly increase.  They 
suggested that DOMS and increased levels of CPK were results of changes in muscle 
tissue structure due to the eccentric contractions performed.  They also proposed that 
DOMS could have been the result of muscles being used in an unaccustomed way.   
Koskinen et al.
11
 conducted a study assessing proteins released into the 
bloodstream from the break-down of extracellular matrix components, after exercise- 
induced muscle damage.  The researchers induced muscle damage in fourteen healthy, 
physically active male volunteers, aged 20-32 years.  The men were separated into two 
groups, with both running at a 10% grade downhill on a treadmill for 45 minutes, but one 
group performed the run at room temperature (22 degrees Celsius) and the other in the 
cold (5 degrees Celsius).  Each subject had venous blood samples taken pre-run, 
immediately post-run, and one, four, and seven days after the run.   
  11 
The results showed that CK increased for both groups, each peaking after one 
day, some reaching four to six times the normal levels, although the participants who ran 
in the cold had significantly higher levels of CK.  Therefore, those who performed in the 
cold temperature experienced more muscle damage.  It was presumed that running in a 
cold environment decreased work capacity and therefore CK levels increased because it 
took increased work and involvement of additional muscle fibers.  The authors felt this 
was more pertinent to the results than the temperature factor. 
Kyrolainen et al.
12
 examined metabolic measurements of seven triathletes 
including one woman and six men, aged 29 ± 5 years, who had volunteered to run a 
marathon.  Blood samples were taken from each subject’s ulnar vein before, during, and 
after the marathon to evaluate levels of serum creatine kinase (S-CK) and plasma skeletal 
troponin I (sTnI).  Finger pricks were taken to determine blood lactate (B-La) levels. 
The presence of CK in the blood reached its peak two to four days following 
intense exercise.  By day six, CK had returned back to normal levels.  STnI levels were 
increased which indicated a disruption in the skeletal muscle cells.  It took approximately 
two days after the marathon for the sTnI levels to return to baseline.  The onset of muscle 
soreness began during the run and did not cease until five days post-marathon.  In 
summary, S-CK levels peaked at two days after the marathon, sTnI two hours after the 
marathon, and B-La remained relatively constant throughout the duration of the testing.  
Muscle damage may be experienced if there is an increase in the levels of 
metabolites in the skeletal muscles or a mechanical disturbance of the muscle cell.  The 
increased levels of S-CK and sTnI that the marathon runners’ experienced was attributed 
to the latter.   
  12 
Kobayashi et al.
13
 was interested in the long term effects of marathon running 
performed by recreational runners.  They wanted to determine how muscle damage 
affected muscle enzymes creatine kinase and lactate dehydrogenase.  Fifteen healthy 
male volunteers took part in this study (mean age 43.5 years).  All had participated in 
endurance training for an average of 50 km/week for 9 years.  The study was performed 
in February at a temperature of between 8 and 10 degrees Celsius.  The participants were 
not allowed to eat or drink the morning of the race.  Before beginning the marathon (flat 
terrain), 10 mL venous blood samples of CK and LDH were taken from an antecubital 
vein to determine baseline levels.  During the race the subjects had fluids available at all 
times.  Ten milliliter blood samples were taken 5 minutes post-race.  The baseline levels 
of serum CK and LDH were within the normal range, 163 U/L and 323 U/L, respectively.  
Subsequent samples were taken on days 1, 2, 3, 7, and 14.  This method of sampling did 
not allow for maximal and minimal values of CK and LDH values during the recovery 
period.   
 CK levels tripled, on average.  One day post-run the values had increased fifteen 
times baseline, then decreased, taking about one week to return to baseline.  LDH levels 
doubled post-race and from there on decreased.  It took about two weeks for LDH to 
return to normal levels.  The subjects participated in very little running during the first 
week post-run due to muscle soreness.  Kobayashi et al.
13
 concluded that CK and LDH 
levels increased in recreational runners after running a marathon, therefore inferring that 
the run caused the muscle damage.  Within two weeks the runners were back to baseline 
and normal training intensity. 
  13 
Pachalis et al.
14
 examined differences in muscle damage between high and low 
intensity eccentric exercise.  The method of exercise was isokinetic quadriceps eccentric 
exercise.  Twelve male subjects, aged 20 to 22 years, participated, all who had no prior 
resistance training experience.  The extent of muscle damage experienced by each subject 
was assessed pre- and post-exercise, 24, 48, 72, and 96 hours after the exercise.  Each 
subject performed two isokinetic quadriceps eccentric exercise sessions on each leg, with 
a 2 week rest period between sessions.  This time period had previously been shown to 
recover muscle damage markers back to baseline.  Each subject participated in high 
intensity (HI) and low intensity (LI) eccentric exercise, with equal work performed doing 
both HI and LI.  Plasma CK and DOMS increased for both HI and LI eccentric exercise, 
however, there was only a significant difference between CK levels 24 hours post-
exercise.  The results indicated that HI and LI exercise had similar effects on muscle 
damage suggesting that muscle damage is caused more by the volume of exercise as 
opposed to the intensity of exercise.   
 Clarkson et al.
15 
had 203 subjects aged 18 to 40 years perform two sets of 25 
maximal eccentric contractions of the elbow flexor on a modified preacher curl bench.  
There was a five minute rest period between each set.  Each contraction lasted for three 
seconds with a subsequent twelve second rest period.  The subjects had to maximally 
contract their elbow flexors to resist the downward movement of a lever controlled by a 
tester.  Subjects were encouraged to remain hydrated pre- and mid-exercise.  Prior to the 
exercise and 4, 7, and 10 days post-exercise, blood samples were drawn to assess renal 
function and muscle damage until blood markers had returned to baseline levels.   
  14 
 Peak CK levels were averaged and reported to be 6420 UL
-1
 on day 4, 2100 UL
-1
 
on day 7, and 311% above baseline on day 10.  The normal CK range was reported to be 
24-195 U/L.  One-hundred eleven subjects had CK levels above 2000 UL
-1
 by day 4 
which has been used to diagnose myositis (an inflammatory muscle disease due to a viral, 
bacterial, or parasitic infection).
16
  Fifty-one subjects (25%) had greater than 10,000 UL
-1
 
which has been associated with rhabdomyolysis (a condition in which there is excessive 
amount of myoglobin in the urine—due to muscle damage).16  The normal range for LDH 
was reported to be 118-273 U/L with the greatest range being 86 - 1608 ± 292 U/L. 
 
  
 LDH levels increased significantly with a strong correlation existing between CK 
and LDH levels (r = .95).  Renal function was not impaired as a result of the elevated 
blood markers.  It was concluded that elevated CK levels, as a result of exercise induced 
muscle damage, did not influence renal function. 
The purpose of Sayers et al.’s17 study was to determine if activity affected the 
recovery of muscle of the elbow flexors after eccentric exercise.  Twenty-six college aged 
men aged 20.8 + 0.9 years who were not weight trained participated in this study.  Each 
subject was randomly assigned to one of three groups:  (1) immobilization—in which the 
subjects’ non-dominant arm was placed in a cast immediately post-exercise for the 
duration of the treatment, (2) control, and (3) light exercise—which consisted of 50 bicep 
curls with 5 lb weights, therefore increasing activity level without causing additional 
muscle damage.  The duration of the study was fifteen days.  For three days baseline 
measurements of relaxed arm angle (RANG), flexed arm angle (FANG), maximal 
isometric force (MIF), and perceived muscle soreness (SOR), were taken.  For four days 
subjects performed 50 maximal eccentric contractions of their non-dominant elbow flexor 
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using a modified preacher curl.  The purpose of this exercise was to induce muscle 
damage.  As the subject applied maximal resistance to perform a curl, an investigator 
used a lever to cause the elbow to extend.  The subjects were asked to resist the lever, 
therefore resisting the action to extend their elbow.  The fifty contractions were split into 
two sets with five minute rest periods, each contraction lasting approximately three 
seconds with a twelve second rest period between contractions.  Treatment was followed 
by eight days of recovery measurements.   
 No significant difference was found among groups over time for baseline RANG, 
FANG, or MIF, though there was a significant main effect for time in RANG, FANG, 
and MIF from before to immediately after eccentric exercise.  There was no significant 
group by time interaction in pre- and post-exercise RANG and MIF, but there was in 
exercise FANG.  The immobilization group had a significantly greater average FANG 
than the control group immediately post exercise.   
 Subjects from all groups experienced an extended decrease in RANG, an increase 
in FANG and SOR, and a decrease in MIF in the days subsequent to exercise.  
Throughout the eight day recovery period no significant group by time interaction was 
found in RANG or FANG, though there was a significant group by time interaction for 
MIF and SOR.  Activity or inactivity did not influence the recovery of the joint angle.   
 No significant difference was found in MIF among the groups until the fourth day 
of recovery, in which the light exercise group had a significantly greater MIF than the 
control group.  From the fifth to the eighth day of recovery the immobilization and light 
exercise group experienced significantly greater MIF than the control group.  No 
significant difference was found between the immobilization and light exercise group 
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throughout the duration of recovery.  Immediately post treatment (day 5) the control 
group had the greatest recovery of baseline MIF of 76%, as opposed to the light exercise 
group (71%), and the immobilization group (68%).  Within the next seven days the 
control group experienced a plateau in recovery, whereas the immobilization and light 
exercise group improved considerably.  No group returned to baseline levels for MIF, but 
90% improvement was experienced by the immobilization group, 88% for the light 
exercise group, and 82% for the control group.   
 A significant group main effect, time main effect, and group by time interaction 
was found in SOR throughout the eight day recovery period.  The immobilization group 
had significantly greater SOR the last day of treatment and the first day of recovery than 
either the control or light exercise group.  After day two there was no longer a 
significantly greater SOR.  All groups had practically returned to baseline levels of SOR 
by the fourth day of recovery. 
 The researchers determined that activity level did influence muscle recovery after 
eccentric exercise of the elbow flexor, with immobilization and light exercise resulting in 
improved muscle function post exercise. 
Hyatt
18
 performed a study to analyze the release and clearance of CK in the 
muscles following two periods of eccentric exercise and to determine if the decrease in 
CK elevation from the first to the second bout of exercise was due to enhanced enzyme 
clearance.  Eight college aged males performed two sets of 50 maximal eccentric exercise 
contractions on a modified preacher-curl bench.  Each set was separated by 5 minutes of 
rest.  Each contraction lasted about 3-5 seconds with a 10-12 second rest period in 
between contractions to prevent fatigue of the exercised muscles.   
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Subjects were randomly assigned to one of two groups, the control (CON) and 
experimental (EXP).  The difference between the groups was that the EXP performed 
eccentric exercises on the opposite arm for the second bout of exercise, whereas the CON 
performed both bouts on the same arm.  Subjects were assessed for 12 consecutive days.  
Blood was drawn for baseline levels on day 1, day 2 the exercise was performed, and day 
3-6 blood samples and criterion measurements were taken, including: range of motion 
(ROM), circumferences (CIR), muscular strength (STR), maximal voluntary contraction 
(MVC), and muscle soreness (SOR), the particular measurement of interest, as it relates 
to the current study.  Subjects were randomly assigned to the CON or EXP group on day 
7, following the same procedure performed in the previous bout of exercise.  
 Soreness was measured using multiple means: a visual analog scale (VAS), self-
palpation (SOR-PALP) and movement (SOR-MVT) by extending and flexing the 
exercised arm.  The VAS scale ranged from 0 (not sure) to 100 (very, very sore).  
Soreness was evaluated pre- and immediately post-exercise and every day thereafter for a 
duration of 5 days per bout of exercise performed.  Blood samples were taken 2, 6, 24, 
48, 72, 96, and 120 hours post-exercise. 
 Similar SOR-MVT and SOR-PALP results were found after the first exercise bout 
and significantly increased following the first exercise in both groups, with no significant 
difference between the two.  The EXP group, which used a different arm to perform the 
second bout of exercise, experienced significantly greater soreness than the CON after 
the second bout of exercise.  The difference between each exercise bout for both groups 
was significant.  
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 The second exercise bout had a similar effect on muscle damage as the first bout, 
though on the opposing arm.  The CON groups second bout was not as influential as the 
first, indicating a repeated-bout effect.  There was an additional effect on ROM, STR, 
CIR, and SOR, but it was not as drastic as the first.   
 The EXP group experienced a similar response post-exercise in ROM, STR, and 
CIR, though not in SOR.  The suspected reasoning for the difference in SOR between 
EXP groups’ bouts was an increased pain tolerance.  The subjects gauged their pain score 
based on there perceived pain from the previous exercise. 
 The second bout of exercise for the CON group, performed within days of one 
another, did not further elevate total creatine kinase levels (TCK), though the EXP 
groups’ TCK rose again.  The study suggests that the TCK blunted response was to due 
to accelerated enzyme clearance by the reticulo-endothelial system.   
 The study reported that the majority of TCK (90%) is found in the muscle (MM) 
isoform, which is further divided into MM1, MM2, and MM3.  Only MM1 is found 
within the muscle, the other two are by-products.  The presence of MM1 in the blood 
indicates freshly released CK from the muscle.  The early release of MMI post-exercise 
bout 1 corresponded with the penetration of neutrophils found within muscle tissue and 
circulating blood.  It is suspected that the increase in the %MM1 could be due to the 
diffusion of neutrophils.  As mentioned, there was a rise in the % of MM1 for the EXP 
and CON group, but less so in the CON group, possibly from muscle fibers that had not 
completely recovered from the first bout, or as a result of additional muscle fiber damage 
to fibers that were not influenced from the first exercise bout.  Post-exercise bout two 
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there was an increase in MM1, a decrease in strength, ROM, and soreness, though less 
than that experienced from bout one.   
 In summary, CK cleared faster after the first bout of exercise and additional CK 
was released in both groups during the second bout of exercise when assessing MM 
isoform data. 
The study by Nosaka et al.
19
 examined the correlation between DOMS and 
indicative measures of muscle damage after performing bouts of eccentric exercises of 
the elbow flexor, similar to those described previously.  One-hundred ten healthy male 
subjects aged 20.3 ± 2.3 years participated in this study.  Fifty subjects were randomly 
selected to perform 12 maximal eccentric exercises (12ECC) of the non-dominant arm’s 
elbow flexor whereas sixty subjects were chosen to perform 24 maximal eccentric 
exercises (24ECC).  Fourteen of the 50 subjects who completed the 12ECC had to 
partake in 60ECC the following year because there were minimal changes in the 
indicative markers of muscle damage.  The exercise required the use of a modified arm 
curl machine in which after 1 s of maximal isometric contraction an investigator 
manipulated the lever the arm was resting on, therefore causing the elbow at 90 degrees 
to extend to 180 degrees in 3 s.  The subjects were asked to resist the force of the 
investigator, therefore resisting the alteration in range of motion.  Fifteen seconds was 
allotted between contraction for each of the groups (12ECC, 24ECC, 60ECC). 
 A modified VAS was used to assess muscle soreness.  The scale ranged from       
0 = ―no pain‖ to 50 = ―unbearable pain‖.  A palpation assessment (SOR-Pal) was 
performed to assess soreness via 3 s of applied pressure to deep tissue of the proximal, 
middle, and distal portion of the biceps brachii by the investigator’s fingers.  A flexion 
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and extension assessment (SOR-Flx and SOR-Ext, respectively) was performed by means 
of an investigator manually moving the subjects’ forearm in a way to maximally flex or 
extend the elbow flexor, while the subjects relaxed their arm.   
 Indirect markers of muscle damage (MIF, RANG, FANG, CIR) were taken pre, 
immediately post, and 1, 2, 3, and 4 days after the eccentric exercises were performed.  
Variations in level of soreness existed among subjects even when similarities in markers 
of muscle damage were present.  The greater the SOR values the greater the degree of 
recovery of MIF.  Ultrasound pictures of the subjects pre, immediately post, and 4 days 
after exercise revealed that there was invariable peak muscle soreness levels though there 
were distinct differences between peak CK levels and the other markers of muscle 
damage.   Therefore, it is suggested that DOMS and muscle damage are not directly 
related.  Nosaka et al.
19
 stated that there is minimal to no relationship between DOMS 
and indicative markers of muscle damage.  
 Nosaka et al.
19
 suggests that subjectivity of the soreness reported could have been 
a resultant of the variability in responses to the eccentric exercise, especially since 
different subjects were used for the 12ECC and 24ECC groups.  Nosaka et al.
19
 stated 
that viable documentation is provided stating that other factors could play a role in the 
soreness response, such as past experiences, personal threshold for pain, mood, and 
health and hormonal status.   
Relationship of DOMS to Inflammation 
Simpson et al.
20
 examined the biological and immune response to hill racing to 
determine the effects a competition had on muscle damage and the acute phase response 
to inflammation.  Seven runners, six males and one female, aged 32 ± 0.8 years, served as 
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subjects.  They all competed a 7 km run and had blood samples taken before the race, 
immediately post-race, and 48 hours post-race to assess skeletal muscle damage markers. 
 The majority of muscle soreness was experienced 48 hours post-race, the same 
time period that it took CK levels to reach their peak.  There was no significant change in 
C-reactive protein (CRP).  Although there was muscle damage and soreness, there was no 
change in acute-phase proteins, which are indicators of inflammation, CRP being one of 
many acute-phase reactants.  No increase in neutrophils, white blood cells that are the 
first to react to inflammation, were found, although a characteristic of neutrophils is that 
they are short-lived and there was presence of immature neutrophils 48 hours post-race.  
It was concluded that the runners experienced muscle damage, but there was no acute 
phase inflammatory response. 
MacIntyre et al.
21
 examined the time-course and relationship between 
inflammation and DOMS following eccentric exercise in twelve healthy males, aged 21 
to 29 years, who exercised less than six hours a week.  At the onset of their participation, 
subjects had eccentric muscle strength tested on the right quadriceps and had 10 mL of 
blood drawn via venipuncture to assess the contractile proteins.  Three hours prior to 
exercise, 100 mL of blood was taken and neutrophils were separated, labeled with a 
contractile protein, and infused back into the subjects prior to exercise.  Each subject 
performed three hundred eccentric repetitions of the right quadriceps muscle using an 
isokinetic dynamometer.  Ten milliters of blood was drawn from the subjects 0, 2, 4, 6, 
20, 24, 48, 72 hours, 6 and 9 days post-exercise to assess DOMS. 
DOMS was the highest immediate post-exercise until 48 hours when it started to 
decline; it disappeared by the ninth day.  Increased levels of contractile protein labeled 
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neutrophils in the quadriceps muscles were present, even though neutrophils have a short 
lifespan as a result of them quickly being transported to the exercised muscle.  The 
researchers found a significant relationship between muscle soreness and inflammation 
and claimed that they were the first to report this relationship. 
In the study by Chleboun et al.,
22
 11 female subjects, aged 20.6 + 1.4 years, 
volunteered to perform eccentric exercises of the elbow flexor.  Muscle soreness, 
isometric strength, stiffness, and swelling measurements were recorded 3 days prior to 
the eccentric contractions, immediately post-exercise, everyday for 5 days, and every 
other day for the next week.   
 Muscle soreness was assessed using a five point scale, 0 = no pain, 1 = pain on 
palpation only, 2 = mild pain with full flexion or extension of the elbow, 3 = significant 
pain with full flexion or extension of the elbow, and 4 = constant pain.  Stiffness was 
assessed by examining the angle and torque of the elbow flexor while performing 
extension exercises and examining relaxed arm angle.  Swelling within the arm was 
determined by alterations in arm circumference and variations in the muscle volume of 
the biceps and brachialis, tricep, and humerus.   
 Peak muscle soreness was experienced 2-3 days post-exercise.  Average pain was 
determined to be 2.9 on day 2 which indicated that the majority of pain was experienced 
when the muscle was being fully extended or flexed as opposed to relaxed.  Minute 
swelling of the elbow flexor was observed immediately post-exercise, rose day 1 and 2, 
reached a plateau by day 3-5 and progressively decreased day 7-11.  Muscle volume 
significantly increased from pre- to post-exercise (days 2-7) by 26.1 + 4.3%.  The whole 
arm also swelled up, but to a lesser extent.  The volume of the elbow flexor muscles was 
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15.6% pre-exercise and 19.1% 3 days post-exercise.  The volume of the subcutaneous 
tissue and cross-sectional area increased, though it was subsequent to the increased 
volume of the elbow flexor muscles.  The significant increase in cross-sectional area size 
was seen post-exercise days 2-7 with peak swelling occurring post-exercise day 3       
(24.2 + 5.2%).  Stiffness significantly increased by 59.9 + 14.1% immediately post-
exercise and remained prominent for 5 days post-exercise.  Elbow angle was significantly 
less by day 3-7 post-exercise.  
The study suggests that muscle swelling is not responsible for muscle stiffness 
experienced 48 hours post-exercise, though it could influence the succeeding stiffness 
experienced.  Chleboun et al.
22
 suggests that extracellular edema is related to tissue 
damage and the resulting inflammation and that intra- and extracellular edema were the 
reason for the swelling of the exercised muscle.  The authors also reason that the delay in 
subcutaneous swelling could be a result of the muscle fluid moving from the exercise 
muscle to the tissue.    
The Relationship of Dehydration to DOMS 
Cleary et al.
23
 performed a study to determine if thermoregulation in a heated 
environment negatively affected muscle damage and DOMS.  Ten healthy male subjects, 
aged 18 to 35 years, volunteered.  All subjects had not participated in any type of lower 
body training for 6 months prior to the study. For the duration of the study they were 
advised to refrain from any treatment that could reduce DOMS such as massage therapy, 
stretching exercises, or anti-inflammatory drugs.  Four variables of DOMS were 
measured: perceived pain, muscle tenderness, passive range of motion, and isometric 
muscle strength.   
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 Baseline information was collected 15 to 20 hours before the study began.  The 
subjects were randomly assigned to two groups, one euhydrated/hyperthermic and the 
other dehydrated/hyperthermic.  Hyperthermia was defined as maintaining an average 
core body temperature of greater than 38 degrees Celsius.  The researchers aimed to get 
the dehydrated group’s body mass down by 3 ± 1%. 
 All subjects participated in a heat stress trial where they walked on a motor-driven 
treadmill in an environmental chamber at a temperature of 40 ± 1.0 degree Celsius and a 
relative humidity of 75 ± 10%.  The temperature and humidity were monitored often to 
verify that exercise was being performed in a hot and humid environment.  The walking 
exercise was performed at a 0 degree grade for a total of 60 minutes, including a 5 minute 
warm-up at 2.5 mi/hr and exercise for 55 min at 3.0 mi/hr.  The dehydrated group was 
restricted from drinking any fluids whereas the euhydrated group was permitted to drink 
cool water at their discretion.   
 At the completion of the 60 minute walk, subjects from both groups had to run 
downhill to induce muscle soreness.  Each subject began the run within 15 minutes of the 
walking exercise to ensure they remained in the hyperthermic state.  The total run time 
was 45 minutes at a negative 12 degree grade, including a 5 minute warm-up and 40 
minutes of running at 5.0 ± 0.2 mi/hr at 50% of their average heart rate.  The run was 
performed in a thermoneutral environment (22 degrees Celsius; relative humidity of 
45%).  Once again, the dehydrated group was not allowed to ingest any fluids whereas 
the euhydrated group could drink water as they wished. 
 The researchers concluded that there was no significant difference between the 
rectal temperature between both groups pre- and post-heat-stress trial.  The dehydrated 
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group had a significant 3.3% decrease in body mass (-2.40 kg), a 44% higher perception 
of pain, a 6.9% increase in punctuate tenderness of the vastus lateralis, and a 6% increase 
in knee-flexion passive range of motion as compared to the euhydrated group.  The 
researchers also concluded that DOMS was caused by downhill running and dehydration 
increased the symptoms associated with DOMS.  The combination of dehydration and a 
hyperthermic condition intensified the degree of microdamage to the skeletal muscles.  
Increasing DOMS reduced the ability to generate force, therefore the researchers 
recommended rehydration to reduce the influence of DOMS.  
Effect of ECP on Recovery After Exercise 
Only one study has previously assessed the effect of ECP on exercise recovery.  
Lezhen
5
 examined the effect of ECP on reducing lactic acid and thus fatigue, probably 
the most comparable study to the one being proposed.  Fourteen men, aged 15 to 19 
years, were subjects for this study.  All subjects were athletes involved in track and field 
and swimming.  After experiencing an unreported ―sublimited load‖ 9 of the subjects 
received ECP treatment, while 5 served as controls.  Blood lactic acid was measured at 
rest and five minutes after performing the ―sublimited load.‖  ECP treatment was 
administered for 50 minutes.  Lactic acid was assessed at 15 and 30 minutes during 
treatment and 10 minutes after the treatment was completed. 
 There was a significant decrease in blood lactic acid after ECP treatment as 
compared to the control group.  Lezhen
5
 concluded that ECP increases the rate at which 
lactic acid is removed from the blood.  The results suggest that ECP increases cardiac 
output, skeletal muscle perfusion, and improves skeletal muscle metabolic function.  
Based on this, it was concluded that ECP treatment may aid in decreasing fatigue.   
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Male and Female Responses to Exercise Induced Muscle Damage 
The purpose of the study by Rinard et al.
24
 was to determine if males and females 
responded differently to high-force eccentric exercise.  Eighty-three women aged         
24.8 + 4.9 years and 82 males aged 24.7 + 5.1 years participated in this study.  They 
performed 70 maximal repetitions of the elbow flexors using a modified preacher bench 
machine which had two cushions keeping the arm from moving.  The investigators had 
control of a mechanical lever which the subjects were to resist. 
 The objective was to produce maximal resistance of the elbow flexor.  Isometric 
strength, resting elbow angle and muscle soreness were assessed prior, immediately post, 
and everyday post-exercise for one week, with muscle soreness being of most importance 
to the present study. 
 Two procedures were used to measure muscle soreness, lifting and palpation.  The 
subjects lifted a 1 lb weight three times through the elbow’s full-range of motion and then 
reported perceived soreness using a 100 mm visual analog scale, with 0 mm = no 
soreness and 100 mm = severe soreness.  The same 100 mm scale was used for assessing 
soreness after palpating the exercised elbow flexor.  The subjects’ loss in strength and 
arm angle immediately post-exercise was similar in males and females, therefore 
experiencing similar exercise stress. 
 Both males and females experienced significant levels of muscle soreness, 
peaking at 32-48 hours post-exercise, with no significant difference between the genders.  
Males’ and females’ relative strength post-exercise and recovery time was the same.  
There was not a significant interaction between gender and time for any of the variables 
tested, even though the women experienced a 27% reduction in strength as opposed to 
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24% experienced by men.  Based on this study’s results, women do not have a lower 
response to eccentric exercise than men.   
 Thompson et al.
25
 conducted a study among thirty-four 18 to 36 year aged women 
in order to determine the relationship between serum creatine kinase activity and 
ovulatory status in exercising and sedentary women.  They found that exercise increased 
women’s CK levels regardless of their menstrual and exercise status.  Normally sedentary 
women’s CK levels increased 33 + 3.4 IU/l whereas the active women’s CK rose from 
47.7 + 3.1 IU/l.  The active women participated in at least 2 hours of activity a week for 
at least 12 months. 
 The women were divided into three groups, ovulating-sedentary, ovulating-active, 
and amenorrheic-active women.  The amenorrheic-active women had significantly 
greater CK levels (54.4 + 3.6 IU/l) than the ovulating-sedentary and ovulatory-active 
groups (33.0 + 3.4 and 43.7 + 4.1 IU/l, respectively).  The ovulating-active group 
consisted of women with various hormone status, 7 with normal hormone environments 
and 8 who were luteal phase deficient, therefore they had reduced luteal phase 
progesterone levels.  When the hormone status was evaluated in the ovulating-active 
women, those who were luteal phase deficient had significantly greater CK levels.  
Therefore, exercise was the primary influence on CK levels in women with normal 
hormone status as opposed to those who were progesterone deficient (51.9 + 5.4 and   
36.6 + 5.2 IU/l, respectively). 
Kostopoulos et al.
26
 examined muscle soreness, damage, and physical 
performance after 10 minutes of intense basketball-simulated exercise.  Forty-eight men 
served as subjects for this study, half with chronic compartment syndrome (CACS) and 
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the other half without CACS.  The ones without CACS were aged 19.55 ± 1.04 years.  
(From this point on the subjects referred to are those without CACS). 
The 10 minute stimulation was representative of a real basketball game’s 
intensity.  The drill included dribbling, shooting, jumping, and forward and backward 
running.  This stimulation was performed by each subject 5 times in one week.  The 
actual experimental procedure consisted of the subjects warming up with a light jog and 
stretching routine.  The subjects caught a basketball from a chest pass thrown to them 
from a distance of 5 m from the three-point line.  From that location the subjects ran and 
dribbled to the basket, stopped with both feet on the floor, parallel distance from the  
free-throw line, then made a jump shot.  The subjects ran back to their starting position 
and repeated the drill.  They continued with this drill for a duration of 10 minutes.   
  Muscle soreness was assessed using a modified ordinal scale which ranged from 
1 = no soreness to 10 = very, very sore.  CK and LDH blood markers were two means of 
measuring muscle damage.  CK activity was significantly increased immediately       
post-exercise, remained elevated until 48 hours post exercise, and returned back to 
baseline 72 and 96 hours post-exercise.  LDH activity was also significantly elevated 
post-exercise, reached a plateau day 2 post-exercise, and back to baseline by day 3 post-
exercise.  Significant increases in muscle soreness were experienced immediately post-
exercise and returned back to baseline levels by day 3 post-exercise. 
Therefore, Kostopoulos et al.
26
 concluded that intense basketball causes skeletal 
muscle damage, a significant rise in CK and LDH activity, and muscle soreness. 
Milias et al.
27
 determined the role inflammation played in DOMS.  They 
examined blood markers pre- and post-eccentric exercise of the elbow flexor of the  
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non-dominant arm using a motorized muscle dynamometer.  Thirteen male subjects, aged 
27.5  3.78 years, participated in this study.  Each subject performed 6 sets of 6 
repetitions producing maximum force of the elbow flexor, starting at an elbow angle of 
110 degrees and ending at 20 degrees.  Ten seconds of rest was taken between each 
repetition and 1 minute of rest was taken between each set.   
 Venous blood samples were drawn pre-exercise and 2, 24, 48, 72, and 96 hours 
post-exercise to examine the levels of CK, LDH, and CRP.  Degree of muscle soreness 
was assessed using a visual analog scale (VAS) and a present pain index (PPI), from 0 
cm = no pain to 10 cm = very painful and 0 = no pain to 5 = excruciating, respectively.  
Soreness was assessed after palpation of the bicep. 
 CK and LDH levels were significantly different post-exercise, significantly 
increasing at 24 hours post-exercise and maxing at 96 hours post-exercise.  No significant 
differences in CRP were seen throughout the duration of the study.  No significant 
difference was seen between the two assessments of muscle soreness, though soreness 
was significant as compared to pre-exercise levels.  Muscle soreness progressively 
increased until 48 hours post-exercise then gradually decreased.  Milias et al.
27
 suggests 
that there was no significant change in CRP because there was no endurance component 
to the exercise protocol and that significant levels of CK and LDH activity were a result 
of muscle damage due to maximal knee flexions.  The changes in muscle soreness 
revealed progressive recovery 48 hours post-exercise. 
 Paschalis et al.
28
 examined the effects eccentric exercise induced muscle damage 
had on gait biomechanics.  To examine the effect on walking and running kinematics the 
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researchers induced muscle damage of the knee extensors of 10 male college students 
aged 20  1 year performing 6 sets of 10 maximal knee flexions.   
 Muscle damage and DOMS was assessed pre- and 48 hours post-eccentric 
exercise (the researchers justified this time of testing based on previous researchers’ 
findings that muscle damage appears 12-24 hours post-exercise and peaks at 24-72 hours 
post-exercise).  CK and LDH blood markers were significantly elevated 48 hours       
post-exercise.  Normal reference range was 45-130 IU and 120-240 IU, respectively.  At 
48 hours post-exercise CK and LDH values were 1370  1527 IU and 268  145 IU, 
respectively.  DOMS was assessed after palpation of the muscle belly based on a 
perceived soreness scale ranging from 1 (normal) to 10 (very, very sore). 
 Jamurtas et al.
29
 examined the differences between leg and arm exercises of the 
same relative intensity on indices of muscle damage.  Three indices of particular interest 
were DOMS, CK, and LDH activity.  Eleven males aged 21.2  1.0 years participated in 
this study, each performing 2 sets of sub-maximal arm and leg exercises for 5 
consecutive days, separated by at least 2 weeks, with 6 subjects’ first set being the leg 
exercise and the other 5 subjects being the arm exercises.  Exercises were performed on 
an isokinetic dynamometer.  Six sets of 12 eccentric actions were performed, with 2 
minutes of rest between sets.  The intensity of exercise was determined to be 75.2 ± 4.1% 
and 76.6 ± 3.5% of eccentric peak torque of the legs and arms, respectively.   
 DOMS was determined by self-palpation of the leg muscle and the elbow flexor 
based on a perceived pain scale ranging from 1 = normal to 10 = very, very sore.  Blood 
was drawn from the antecubital vein to assess CK and LDH activity.  All determinants of 
muscle damage were assessed pre-exercise and 24, 48, 72, and 96 hours post-exercise.  
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The normal reference range for CK and LDH in this study was 45-130 IU L
-1
 and       
120-240 IU L
-1
, respectively. 
 DOMS from the leg exercise peaked at 48 hours post-exercise and still remained 
elevated by 96 hours post-exercise.  DOMS of the arms was significantly greater than the 
legs at 72 and 96 hours post-exercise.  Leg CK activity significantly increased 24 hours 
post-exercise, peaking at 96 hours post-exercise.  Peak CK activity ranged from 79-1,787 
IU L
-1
.  LDH, on the other hand, did not significantly increase.  The peak CK in the arms 
was significantly greater, 135 - 14,995 IU L
-1
, but LDH significantly increased 24 - 96 
hours post-exercise for the arms.  The arms had significantly greater increases in enzyme 
activities than the legs.   
 Muscle damage was significantly greater in the arms than the legs.  Recovery time 
was significantly greater for the arm elbow flexors than the knee extensors.  
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CHAPTER III 
 METHODS  
 
 An experimental research design was used.  The independent variable was ECP 
treatment vs. no ECP treatment.  The dependent variables were measures of DOMS     
(i.e. pain, serum CK, LDH, and C-reactive protein levels).  The ECP method used in this 
study was validated by ScottCare Incorporation (Cleveland, OH). 
Subjects 
 Ten trained runners, 5 males and 5 females, aged 19 to 52 years from Cleveland 
State University and the Cleveland area served as subjects.  Subjects reported to 
Cleveland State University’s (CSU) Human Performance Laboratory for a pre-
participation screening questionnaire to determine eligibility (Appendix A).  Subjects 
were excluded if they had a history of musculoskeletal problems or any predisposed 
health problem that placed them at risk for injury.  All subjects were trained and capable 
of completing a twenty mile run at 70% of their age-predicted maximal heart rate.  After 
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determining eligibility, each subject signed an informed consent form approved by the 
Institutional Review Board at CSU (Appendix B).  Subjects were asked to refrain from 
training forty-eight hours prior to their initial test.   
Experimental Procedures 
 Each subject completed a pre-measured twenty mile course on relatively flat 
terrain, with a total elevation change of 579 ft (176 m) and a total climb of 256 ft (78 m).  
Venous blood samples were obtained from the antecubital vein prior to the run to 
establish baseline levels for creatine kinase (CK) and lactate dehydrogenase (LDH).  CK 
and LDH analysis was performed by Saint Vincent Charity Hospital’s Biochemistry 
Laboratory (Cleveland, OH).  C-reactive protein (CRP) was measured to determine 
inflammation; a 50 µL sample was obtained with a finger stick.  The sample was 
analyzed on the Cholestech LDX analyzer in the CSU Human Performance Laboratory.  
Weight was obtained pre- and post-run; heart rate and blood pressure were obtained 
before and after each ECP treatment; heart rate, pulse pressure, and oxygen saturation 
were obtained continuously during ECP treatment.  Blood pressure was taken with a 
stethoscope and a sphygnomonmeter, resting heart rate was measured using ECG, pulse 
pressure and arterial oxygen saturation was measured via finger pulse oximeter, height 
was measured using a stadiometer, and weight was measured using a physician’s beam 
scale.   
 Subjects then completed a twenty mile run at an intensity of at least 70% of their 
age-predicted maximal heart rate (220-age).  Each subject wore a Polar™ heart rate 
monitor to determine running intensity.  Subjects were provided Gatorade® Original 
Lemon-Lime sports beverage approximately every three miles to prevent dehydration.  
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Fluid-intake was monitored and recorded.  At the conclusion of the twenty mile run, 
blood samples were obtained and the subject’s vital signs were measured again.  The 
subjects were randomly assigned to the treatment or control trial to avoid order effect; 
therefore half of the runners received the ECP treatment after the first run and half 
received the ECP treatment after the second run.  Time between trials was approximately 
three to four weeks, based on subject and researcher availability.  Regardless of trial, 
post-run weight was measured. During the control trial, subjects reported daily for blood 
samples without treatment until all blood levels had returned to baseline levels.  During 
the treatment trial, subjects were treated with ECP for 5 consecutive days, at the same 
time of day, until all blood markers returned to baseline levels.  For both conditions, 
muscle pain was assessed using the Management of Cancer Pain Scale
30,31
 (Appendix C). 
ECP Treatment 
 Prior to ECP treatment, each subject was sized for pressure cuffs to assure proper 
cuff inflation and treatment pants (i.e. tights) were worn to prevent irritation from the 
pressure cuffs.  
 The ECP treatment was performed in the Human Performance Laboratory at 
CSU.  ECP treatment required subjects to lie supine on a table and have pneumatic 
compression cuffs placed around the calves, thighs, and buttocks.  Electrodes were placed 
on the subject to monitor the electrocardiogram tracing (ECG) (Appendix D).  Guidelines 
developed by ScottCare were followed for all ECP treatments. 
When treatment began, both arms remained relaxed at the side of the body 
(Appendix E).  The head of the bed was at no more than a 30 degree angle; preferably 
flat, to prevent occlusion of blood to the femoral arteries.  The 60 minute ECP treatment 
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procedure allowed for a 5 minute warm-up at a low pressure (between 1 and 3 psi) in 
order to gradually increase the diastolic pressure, allowing the subject to become 
acclimated to the pressure.  The cuffs inflated sequentially at 50 ms intervals, distal to 
proximal and deflated simultaneously (Figure 1).
31
                                                                                                                                                                                     
 
Figure 1.  Sequential inflation and deflation of pneumatic cuffs during ECP 
treatment 
  After 5 minutes, psi was increased to a therapeutic peak-to-peak ratio (P/P ratio) 
of 1.2 or greater.  The maximum pressure allowed was 6 psi, a safety regulation 
established by the manufacturers.  The pressure intensity needed to be maintained at a 
comfortable and therapeutic level.  Treatment ceased with any complaints of discomfort 
from the subject.  Potential adverse side effects from ECP are skin irritation due the 
pneumatic compression cuffs, muscle aches, or headaches, though minimal and        
short-lived.
27
    
The timing of the cuffs’ inflation or deflation depended on whether the heart was 
in diastole or systole, working in conjunction with the ECG.  The timing was important to 
assure proper timing of the treatment during the cardiac cycle.  The cuffs were used to 
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apply varying amounts of pressure to the arteries and veins.  Inflation causes an increase 
in venous return to the heart which results in an increased end diastolic volume, therefore 
stroke volume and cardiac output increase.  The inflation of the cuffs causes a change in 
blood volume and pressure in the aorta which in turn increases the volume and pressure 
in the coronary arteries.  This increase in diastolic pressure increases perfusion to the 
heart.  The increase in arterial pressure causes diastolic augmentation.  When the 
compression cuffs deflate, it results in blood flowing back through the buttocks, thighs, 
and calves to return the pressure in the aortic cavity back to normal.  Timing this 
correctly was important to make sure that deflation occurred in the early phase of systole 
so that it decreased the force with which the heart had to work, therefore decreasing 
myocardial oxygen requirement.
1
 
The researchers were present through the duration of the treatment to ensure the 
subject’s comfort and safety, and to monitor data collection.  Every 10 minutes, a manual 
P/P ratio was performed by the researcher to assure the proper timing of the inflation and 
deflation of the cuffs (Appendix F).  Upon completion of each treatment, blood pressure 
and heart rate were recorded.   
Regardless of experimental condition, subjects were asked to record all activities 
5 days post-run and replicate those same activities for each of the 2 trials as a means of 
controlling extraneous variables. 
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Control Group Treatment 
 To determine if muscle damage and inflammation resulted from ECP treatment 
alone, void any form of exercise, five additional subjects received ECP treatment for 5 
consecutive days.  Subjects were asked to abstain from exercise prior to and throughout 
the duration of the treatment. 
Maximal Oxygen Consumption (VO2 max) 
 The ten trained runners performed a VO2 max treadmill test subsequent to 
complete recovery from both 20 mile runs.  Indirect calorimetry was used to measure 
VO2 max in the Human Performance Laboratory at CSU using a metabolic cart 
(Physiodyne™) under the direct supervision of a trained professional.  Measuring the 
subjects’ aerobic capacity and maximal heart rate made it feasible to determine what 
percentage of maximal heart rate and maximal oxygen consumption was achieved during 
the runs.  These values were calculated using the speed and time of each subject’s run 
using the following equation: VO2 (ml·kg
-1
·min
-1
) = speed (m/min) x .2 + 3.5 ml.
7 
Statistical Analysis 
 Descriptive statistics were obtained on all measures.  A repeated measures 
ANOVA was used to assess treatment differences due to the independent variable, ECP 
treatment vs. no ECP treatment, on the dependent variables, pain, CK, LDH, and           
C-reactive protein blood markers.  Protected t-tests were used to determine significant 
differences across serial markers.  Correlations were run among the dependent variables 
to determine if any significant relationships existed.  SPSS-PC (version 14.0) was used 
for all analyses with 0.05 used as the level of significance. 
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CHAPTER IV 
RESULTS & DISCUSSION 
Control Group (ECP only) 
In order to validate that running was responsible for the changes in DOMS and 
inflammation, as opposed to the ECP treatment itself, a control group, which included 5 
additional subjects, underwent 5 days of ECP treatment. 
  Table 1.  Control group subjects’ characteristics.  
Control Group 
(ECP only) 
Males (N=3) Females (N=2) Total Group (N=5) 
Height (cm) 
 
187.1 ± 14.0 168.3 ± 8.1 179.6 ± 13.3 
Weight (kg) 
 
92.4 ± 19.9 65.0 ± 3.2 81.5 ± 20.6 
Age (yrs) 
 
26.3 ± 0.6 24.5 ± 3.5 25.6 ± 2.1 
Values are mean ± standard deviation 
The control group abstained from exercise prior to and throughout the duration of 
the treatment to avoid experiencing any acute muscle damage.  No significant difference 
was observed among any of the biochemical blood markers from pre- to post-treatment 
days (Table 2, Table 3, Table 4). 
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C-reactive protein (CRP) 
The control group’s CRP remained within the normal range throughout the 5 day 
treatment period, with no significant difference in inflammation from pre- to Day 5 post-
treatment (Table 2).  The normal range for CRP is between 1.00 and 3.00 mg/L. 
Table 2. CRP results with ECP treatment in the control group. 
Condition 
(N=5) 
Mean Std. Deviation p-value 
Pre-treatment 1.70  .91 ----- 
Day 1 1.96 1.05 .612 
Day 2 1.83 1.40 .852 
Day 3 1.61 1.24 .901 
Day 4 1.48 1.05 .726 
Day 5 1.42 1.17 .671 
Normal = 1.00-3.00 mg/L 
 
Lactate Dehydrogenase (LDH) 
The control group’s LDH remained within normal range throughout the 5 day 
treatment period, with no significant difference from pre- to Day 5 post-treatment   
(Table 3).  
Table 3.  LDH results with ECP treatment in the control group. 
Condition (N=5) Mean Std. Deviation p-value 
Pre-treatment 164.8 29.0 ----- 
Day 1 164.2 27.5 .946 
Day 2 165.6 33.9 .960 
Day 3 168.0 32.7 .670 
Day 4 149.4 26.0 .213 
Day 5 154.6 28.1 .280 
Normal =75-190 (U/L) 
 
 
Creatine Kinase (CK) 
 
The control group’s CK increased beyond the normal range peaking at Day 2 of 
treatment (Table 4).  However, these differences were not significant.   
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Table 4. CK results with ECP treatment in the control group. 
Condition (N=5) Mean Std. Deviation p-value 
Pre-treatment 193.0 192.7 ----- 
Day 1 264.4 154.3 .343 
Day 2 316.0 264.0 .374 
Day 3 256.4 196.2 .411 
Day 4 223.6           97.5 .735 
Day 5 188.2           73.8 .938 
Normal = 21-232 (U/L) 
 
Experimental Protocol 
 The experimental group consisted of the ten subjects who ran 20 miles under 
control conditions and ECP treatment conditions.  Subject characteristics for the 
experimental group (N = 10) are presented in Table 5.  
Table 5. Experimental groups subjects’ characteristics. 
Experimental Group 
(Control Run vs. ECP 
Treatment Run) 
Males (N=5) Females (N=5) Total Group (N=10) 
Height (cm) 
 
186.3 ± 12.8 164.1 ± 4.6 179.1 ± 12.5 
Weight (kg) 
 
71.1 ± 8.3 58.8 ± 3.1 64.9 ± 8.7 
Age (yrs) 
 
34.2 ± 11.5 26.8 ± 14.1 30.5 ± 12.8 
VO2 max (ml•kg
-1•min-1) 
 
57.5 ± 8.2 48.3 ± 5.6 52.9 ± 8.2 
Values are mean ± standard deviation 
 Males were found to be significantly taller and weigh significantly more than the 
females in the experimental group.  No significant difference in age or VO2max was seen 
between genders (Table 6). 
 
 
 
  41 
Table 6.  Gender comparison of height, weight, age, and VO2 max in the 
experimental group. 
Condition (N = 10) Mean ± SD p-value 
Male—female height 13.208 ± 5.507     .006 * 
Male—female weight 12.294 ± 5.464    .007 * 
Male—female age     7.400 ± 15.307 .341 
Male—female VO2 max   9.212 ± 8.194 .066 
*Significant difference (p < .05) 
 
 There was no significant difference in mean weight loss, fluid intake, heart rate, 
percentage of maximum heart rate, percentage of VO2 max, or running time during the 
run for the two trials (p ≥ .05) (Table 7). 
Table 7.  Comparison between ECP treatment run and control run for the 
experimental group. 
Condition (N=10) Control Treatment Mean Difference p-value 
Weight loss (kg)  1.7 ± 1.0  1.1 ± 0.7 0.5 ± 0.8 .062 
Fluid intake (ml) 1650.0 ± 807.7 1787.0 ± 650.2 136.9 ± 470.7 .382 
HR (bpm) 162.8 ± 15.6 160.0 ± 14.2 2.8 ± 9.7 .383 
% Max HR 87.4 ± 5.7 86.0 ± 7.1 1.3 ± 4.9 .404 
%VO2 Max 72.8 ± 6.1 71.3 ± 9.2 1.4 ± 4.9 .380 
Running time (min) 189.3 ± 30.6 194.3 ± 27.8 5.0 ± 17.7 .400 
Values are mean ± standard deviation 
Indicators of Muscle Damage and Inflammation 
C-reactive protein, pain, CK, and LDH variables were analyzed using a repeated 
measures ANOVA.  Multiple comparisons were determined using protected t-tests to 
control for Type I error inflation.   
C-reactive protein (CRP) 
 According to the literature, a change in acute-phase proteins is indicated by the 
significant elevation in CRP
19
, as supported by the results (Table 8).  C-reactive protein 
elevation peaked Day 1 post-control and ECP treatment runs.  Significantly elevated CRP 
was present from Day 1 to Day 3 post-control run, but only Day 1 of ECP treatment run.  
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Normal CRP range was obtained by Day 4 post-control and post-treatment runs.  
Therefore, treatment reduced CRP elevation by 40% (Table 8).   
Table 8.  CRP results for the control run and ECP treatment run.  
Condition (N=10) Mean Std. Deviation p-value 
Pre - Control Run  1.18 0.92 ---- 
Post - Control Run 1.13 0.77  .405 
Day 1 Control Run 6.88 3.22              .000   * 
Day 2 Control Run 4.20 2.26              .001   * 
Day 3 Control Run 3.01 1.70              .005   * 
Day 4 Control Run 1.73 0.84 .135 
Day 5 Control Run 1.66 1.11 .292 
    
Pre - ECP Treatment Run 1.86 2.18 ---- 
Post - ECP Treatment Run 2.05 2.51 .167 
Day 1 ECP Treatment Run 7.23 3.27              .001   * 
Day 2 ECP Treatment Run 5.01 2.67              .011    
Day 3 ECP Treatment Run 3.42 2.51 .167 
Day 4 ECP Treatment Run 2.80 3.61 .505 
Day 5 ECP Treatment Run 2.64 4.28 .626 
Normal = 1.00-3.00 mg/L 
*Significant difference from Pre- (protected t-test, p  < .01) 
 
Simpson et al
20
 showed no significant difference in CRP, even though muscle 
damage was present.  It can be suggested that muscle damage does not equate to 
inflammation.  CRP has been associated with the endurance component of exercise     
(i.e. eccentric cycling until exhaustion, downhill running)
27 
, which would aid in 
explaining the significantly elevated CRP levels observed in the ten subjects following 
each run.   
Pain 
Perceived pain was recorded immediately post to Day 5 post-runs.  The perceived 
pain scale ranged from 0 – 10, with 0 = no pain and 10 = unbearable pain.  Subjects’ pain 
peaked immediately post-runs (Table 9).  Pain was still present Day 5 post-control run, 
but had diminished by Day 4 of the ECP treatment run.  A 20% reduction in significant 
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pain elevation was experienced from ECP treatment (Table 9). Therefore hypothesis one 
was accepted; ECP treatment reduced the delayed onset of muscle soreness (DOMS).   
Table 9. Pain results for the control run and ECP treatment run. 
Condition (N=10) Mean Std. Deviation p-value 
Pre - Control Run  0.0 ----  ---- 
Post - Control Run 6.6 2.4           .000   * 
Day 1 Control Run 4.9 2.4           .000   * 
Day 2 Control Run 2.8 2.5           .006   * 
Day 3 Control Run 1.4 1.4           .013    
Day 4 Control Run 0.4 0.8  .168 
Day 5 Control Run 0.3 0.7  .193 
    
Pre - ECP Treatment Run 0.0 ----  ---- 
Post - ECP Treatment Run 5.7 2.2           .000   * 
Day 1 ECP Treatment Run 3.3 2.7           .004   * 
Day 2 ECP Treatment Run 1.2 1.7  .051 
Day 3 ECP Treatment Run 0.3 0.5  .177 
Day 4 ECP Treatment Run 0.0 ---- ---- 
Day 5 ECP Treatment Run 0.0 ---- ---- 
Scale 0 (no pain) - 10 (unbearable pain) 
*Significant difference from Pre- (protected t-test, p < .01) 
 
 It was foreseen that subjects would likely gauge pain of the second run based on 
pain experienced during the first run.  It was important to account for these potential 
discrepancies by having 5 subjects experience treatment the first run and 5 subjects 
experience the non-treatment condition the first run, therefore accounting for order effect.  
Nosaka et al.
19
 found variations in levels of muscle soreness even when similarities in 
markers of muscle damage were present and suggested that other factors can influence  
pain perception such as past experiences, pain threshold, mood, health and hormonal 
status.  Coincidentally, subjects in the present study verbalized their thought process 
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about pain perceived, stating how the pain from the second run differed or compared to 
the first run.  
 Although there were no objective means of measuring exercise tolerance, the 
perceived pain (via pain scale) decreased faster while undergoing ECP, as compared to 
the control condition.  This suggests that the intensity and duration of exercise post-
treatment could return to that achieved prior to the run quicker, hence increasing exercise 
tolerance.  Other studies have shown that an increase in myocardial perfusion increased 
exercise tolerance for CAD patients.
3,8,9  
 The same may be true for trained runners.   
Schwane et al.
10 
found no significant measurement of muscle soreness after a 45 
minute run on level ground.  Even though the ground in the current study was fairly level, 
there was a slight variation in the elevation (579 feet), whereas on the treadmill in the 
study by Schwane et al.
10
, a 0% grade remained constant.  Therefore, some of the muscle 
soreness experienced by the runners may have been due to the slight variation in 
elevation in addition to the greater volume of exercise. 
The subjects in the current study reported the highest degree of pain immediately 
post-run, which agrees with MacIntyre et al.
21
 who reported peak muscle soreness 
immediately post-marathon until 48 hours after eccentric exercise of the quadriceps 
muscle.
 
Lactate Dehydrogenase (LDH) 
 Lactate dehydrogenase elevation peaked post-runs and returned to normal range 
(75-190 U/L) by Day 1 for the experimental group (Table 10).  Lactate dehydrogenase 
was significantly elevated immediately post to Day 2 post-control run.  Significantly 
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elevated LDH levels decreased by 20% due to the ECP treatment, subsiding by Day 1 
post-run (Table 10). 
Table 10.  LDH results for the control run and ECP treatment run. 
Condition (N=10) Mean Std. 
Deviation 
p-value 
Pre -  Control Run  151.4 12.4     ---- 
Post - Control Run 244.1 36.0            .000   * 
Day 1 Control Run 177.3 18.9            .003   * 
Day 2 Control Run 178.5 21.7            .003   * 
Day 3 Control Run 175.6 36.4    .054 
Day 4 Control Run 164.4 23.8    .076 
Day 5 Control Run 161.2 22.9    .146 
    
Pre - ECP Treatment Run 157.8 20.5    ---- 
Post - ECP Treatment Run 234.1 37.7            .000   * 
Day 1 ECP Treatment Run 186.4 17.8            .000   * 
Day 2 ECP Treatment Run 180.6 19.2            .012    
Day 3 ECP Treatment Run 177.1 23.7            .011    
Day 4 ECP Treatment Run 169.1 22.1    .069 
Day 5 ECP Treatment Run 169.3 22.5    .061 
Normal =75-190 U/L 
*Significant difference from Pre- (protected t-test, p < .01) 
 
 In the study by Schwane et al.
10
 no significant change in LDH was found        
post-race.  It could be speculated that the longer duration of the present study (mean 
duration ~192 minutes), as opposed to the 45 minutes of running experienced by subjects 
in the study by Schwane et al.
10
, could have influenced the significant rise in LDH.  
Schwane et al.
10
 suggested that DOMS was a result of the changes in muscle structure 
caused by the eccentric contractions performed throughout the run.  Muscle damage may 
be experienced if there is an increase in the levels of metabolites in the skeletal muscles 
or a mechanical disturbance of the muscle cell which can occur from running, especially 
of long duration.
12 
 Pachalis et al.
14
 suggested that muscle damage is due more to volume 
as opposed to intensity of exercise.
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Creatine Kinase (CK) 
Creatine kinase elevation peaked Day 1 post-runs (Table 11).  Significantly 
elevated CK levels were present immediately post and Day 1 post-control run, whereas 
significantly elevated CK levels post-ECP treatment run were present immediately post 
and Day 4 post-run.  Normal CK range (21-232 U/L) was obtained by Day 3 post-control 
run and Day 4 post-ECP treatment run (Table 11).  
Table 11.  CK results for the control run and ECP treatment run. 
Condition (N=10) Mean Std. 
Deviation 
p-value 
Pre - Control Run  150.2 104.4    ---- 
Post - Control Run 322.0 140.7            .000   * 
Day 1 Control Run 574.8 326.5            .004   * 
Day 2 Control Run 330.0 158.0            .011    
Day 3 Control Run 216.5 120.9            .142 
Day 4 Control Run 201.9 164.9    .405 
Day 5 Control Run 174.5 109.1    .596 
    
Pre - ECP Treatment Run 126.1         85.1    ---- 
Post - ECP Treatment Run 269.9 131.4           .000    * 
Day 1 ECP Treatment Run 602.90 373.5           .003    * 
Day 2 ECP Treatment Run 363.3 163.2           .001    * 
Day 3 ECP Treatment Run 287.30 100.6           .002    * 
Day 4 ECP Treatment Run 224.3          84.6           .004    * 
Day 5 ECP Treatment Run 192.1          61.3           .043    
Normal = 21-132 (U/L) 
*Significant difference from Pre- (protected t-test, p < .01) 
 
This study agrees with previous research by Schwane et al.
10  
that found a 
significant increase in CK after running for 45 minutes at a 10% grade downhill.  The 
increased level of CK was attributed to changes in muscle structure caused by the 
eccentric contractions performed throughout the run.  It also agrees with Jamurtas et al.,
29
 
who studied the differences between eccentric exercises of the elbow flexors and legs at 
the same relative intensity, found CK activity to significantly increase 24 hours          
post-exercise, the same time period that CK elevation peaked in the present study.  
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Hypothesis two of this study stated that ECP treatment would reduce the biochemical 
markers of muscle damage (CRP, LDH, and CK).  The hypothesis is accepted for CRP 
and LDH, but rejected for CK, suggesting that other factors could be responsible for these 
differences.  Some of these differences could be due to variations in environmental 
conditions.  Research has shown that running in colder temperatures results in higher 
levels of CK, therefore suggesting an increase in muscle damage.
11  
It is presumed that 
running in a colder environment decreases an individual’s ability to perform work, 
causing the recruitment of more muscle fibers to complete the run.
11  
In this study the two 
runs were scheduled periodically beginning in March and ending in late August of 2007.  
Even though each of the runners’ two runs was scheduled within 3 to 4 weeks of each 
other to minimize the variations in temperature, the two runs were not performed under 
identical conditions.    
Comparisons between DOMS, CK, LDH, and CRP 
 Numerous studies have examined the effects of eccentric exercise using the elbow 
flexors on DOMS, CK, LDH, and CRP.  Though the indices of muscle damage are the 
same, variations have been shown to exist between eccentric exercise performed on the 
arms and legs (as mentioned previously).  Arm exercises have been shown to elicit 
greater DOMS, CK, and LDH activity than the legs.  Overall, muscle damage is 
significantly greater in the arms, resulting in greater recovery time.  It is suggested that 
changes and trends in CK, LDH, and DOMS are situational, based on the exercise 
protocol administered.  It is noteworthy to recognize that studies reporting indices of 
muscle damage of the elbow flexors may not accurately represent the trends in blood 
markers and DOMS following eccentric exercise of the lower extremities.   
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 Literature reviewed throughout this study often mentioned peak levels of CK, 
LDH, CRP, and DOMS that differed from the present study, though they did not account 
for all the days post-exercise to recovery, therefore not providing the most ideal means of 
comparison.
15,20,21,27,28,29
  The greatest elevation among the dependent variables in the 
present study was observed immediately post or Day 1 post-exercise.  It is recommended 
that future research studies observing the effects of eccentric exercise on CK, LDH, CRP, 
and DOMS should be measured from the time the exercise is performed until recovery.  
Relationships between Indicators of Muscle Damage and Inflammation 
 Correlations were obtained to determine if relationships existed between DOMS 
and inflammation, DOMS and markers of muscle damage, inflammation and markers of 
muscle damage, and between markers of muscle damage (Table 12).  All significant 
relationships were found post-control run, but none post-ECP treatment run.  The results 
do not exactly coincide with the literature.  Though as mentioned previously, various 
factors can play a role in the elevation of particular enzymes and pain tolerance.   
Table 12.  Relationships between control run variables. 
Variables r r
2
 p-value 
CRP--CK Day 3 .699       .489  .025* 
CRP--CK Day 4 .647       .419  .043* 
CRP--CK Day 5 .803       .645  .005* 
pain--LDH post-run .767       .588  .010* 
CK--LDH Day 5 .693       .480  .026* 
CRP—pain Day 2 .855 .731 .002* 
*Significant difference (p<.05) 
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Relationships between CRP and CK 
 No literature reviewed looked at the relationship between CRP and CK though a 
strong relationship was observed Day 3 and Day 4 (r = .699 and r = .647, respectively) 
and a very strong relationship Day 5 of the control run (r = .803).  C-reactive protein and 
CK were both found to peak Day 1 post-run.  The present researchers claim they are the 
first to report this relationship.   
Relationships between DOMS and LDH 
 Nosaka et al.
19
 found minimal to no relationship between DOMS and markers of 
muscle damage after performing eccentric exercises of the elbow flexors, whereas the 
present study found a significant relationship between LDH and pain post-control run     
(r = .767).  Both variables were also found to peak immediately post-control run. 
 Jamurtas et al.
29
 reasoned that influences of eccentric contractions of the elbow and knee 
flexors are not synonymous.  This could account for this discrepancy.   
Relationships between DOMS and CRP 
 Schwane et al.
10 
found no significant relationship between DOMS and 
inflammation after running at different grades.  However, a strong correlation was  
observed between pain and CRP Day 2 of the control run (r = .855) in this study.  This 
finding agrees with MacIntyre et al.
21
 who claims to have been the first to report a 
relationship between DOMS and inflammation.   This finding also agrees with Chelboun 
et al.
22   
who has suggested that intra and extracellular edema were a result of tissue 
damage and inflammation, respectively.  It could be argued that the delay in peak CRP, 
as compared to pain, was due to muscle fluid transitioning from the exercised muscle to 
the tissue.
22 
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Relationship between CK and LDH 
 There is little research reported for the correlation between CK and LDH.  The 
present study and a study by Clarkson et al.
15
 shows a strong correlation between CK and 
LDH (r = .693 and r = .95, respectively).  More research is needed to clarify this 
relationship. 
Gender Differences in Biochemical Markers of Muscle Damage and Inflammation 
 
 To account for gender differences in biochemical markers of muscle damage and 
inflammation, the analyses were run separately for each gender.   
C-reactive protein (CRP) 
 Both males and females reached peak CRP levels on Day 1 post-runs (Table 13).  
Males experienced elevated, though not significant, levels of CRP until Day 3            
post-control and ECP treatment runs.  Therefore there were no significant differences 
among males’ CRP levels post-control and ECP treatment runs.   Females, on the other 
hand, experienced a 20% increase in CRP from the control to the ECP treatment runs, 
remaining significantly elevated Day 1 and Day 2 post-treatment.  Normal CRP range 
was obtained by Day 4 post-control run, but was still above normal range by Day 5 
post-ECP treatment run.  The additional CRP elevation observed in the females may be 
attributed to the run itself. 
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Table 13.  Gender results for CRP. 
 Males (N=5)  Females (N=5)  
Condition  Mean ± SD p-value Mean ± SD p-value 
Pre - Control Run 1.34 ± 1.26 ---- 1.02 ± 0.51 ---- 
Post - Control Run 1.30 ± 1.00     .765 0.95 ± 0.50 .162 
Day 1 Control Run 6.26 ± 4.18     .043  7.49 ± 2.22       .002   * 
Day 2 Control Run 3.87 ± 2.70  .066 4.53 ± 1.98       .012   
Day 3 Control Run 2.80 ± 1.54  .056 3.21 ± 2.01       .063 
Day 4 Control Run 1.63 ± 0.86  .667 1.84 ± 0.89 .060 
Day 5 Control Run 1.34 ± 0.66   1.000 1.97 ± 1.44 .191 
     
Pre - ECP Treatment Run 2.65 ± 2.92 ---- 1.07 ± 0.76 ---- 
Post - ECP Treatment Run 2.90 ± 3.41 .364    1.19 ± 0.85 .091 
Day 1 ECP Treatment Run 6.47 ± 4.52 .157 7.99 ± 1.49       .000   * 
Day 2 ECP Treatment Run 3.89 ± 2.31 .379 6.12 ± 2.74       .006   * 
Day 3 ECP Treatment Run 2.27 ± 1.31 .776 4.57 ± 3.02       .045    
Day 4 ECP Treatment Run 1.55 ± 1.01 .440 4.04 ± 4.94 .234 
Day 5 ECP Treatment Run 1.29 ± 0.61 .348 3.98 ± 6.02 .328 
Normal = 1.00-3.00 mg/L 
*Significant difference from Pre- (protected t-test, p  < .01) 
 
 
Pain 
 Pain was experienced post-control run for the females and post-ECP treatment run 
for the males and females, peaking immediately post-runs (Table 14).  Both males and 
females experienced a 20% reduction in pain due to treatment, though females 
experienced pain one day longer post-control and ECP treatment runs, as compared to the 
males.  It was clearly evident that males had a higher pressure tolerance exuded by the 
compression cuffs than the females.  The females often requested the pressure to be 
decreased whereas the males, more times than not, requested the pressure to be as high as 
they could tolerate. 
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Table 14.  Gender results for pain. 
 Males (N=5)  Females (N=5)  
Condition  Mean ± SD p-value Mean ± SD p-value 
Pre - Control Run  0.0 ---- 0.0 ---- 
Post - Control Run 5.7 ± 3.0    .013  7.5 ± 1.6    .000 * 
Day 1 Control Run 4.5 ± 2.5    .016  5.2 ± 2.6  .011  
Day 2 Control Run 2.4 ± 1.0    .080 3.2 ± 2.9 .067 
Day 3 Control Run 1.0 ± 1.0    .089 1.8 ± 1.8 .088 
Day 4 Control Run 0.0      ----  .8 ± 1.1 .178 
Day 5 Control Run 0.0      ----          .6 ±   .9 .208 
     
Pre - ECP Treatment Run 0.0 ---- 0.0 ---- 
Post - ECP Treatment Run 4.3 ± 2.1    .010 * 7.0 ± 1.4   .000* 
Day 1 ECP Treatment Run 1.6 ± 1.3    .056 5.0 ± 2.6  .013 
Day 2 ECP Treatment Run 0.2 ± 0.4    .374 2.2 ± 1.9 .063 
Day 3 ECP Treatment Run 0.0 ---- 0.5 ± 0.7 .189 
Day 4 ECP Treatment Run 0.0 ---- 0.0 ---- 
Day 5 ECP Treatment Run 0.0 ---- 0.0 ---- 
Scale 0 (no pain) –10 (unbearable pain) 
*Significant difference from Pre- (protected t-test, p  < .01) 
 
 
Lactate Dehydrogenase (LDH) 
 Both males and females reached peak LDH levels post-runs (Table 15).  Males 
experienced significantly elevated LDH levels post-treatment run and females            
post- treatment run and Day 1.  During the control run only females experienced a 
significant change post-run.  They experienced a 20% increase in LDH elevation  
post-ECP treatment run which is likely attributed to the run itself.  Males experienced a 
significant change on Day 4 of the control run.  It is unclear as to what attributed to this 
occurrence.  It may be due to subject variability response. 
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Table 15.  Gender results for LDH.   
 Males (N=5)  Females (N=5)  
Condition  Mean ± SD p-value Mean ± SD p-value 
Pre - Control Run  151.2 ± 13.5 ---- 151.6 ± 12.8 ---- 
Post - Control Run 233.8 ± 46.4 .019  254.4 ± 22.4   .000 * 
Day 1 Control Run 176.2 ± 15.5 .084 178.4 ± 23.6      .029  
Day 2 Control Run 181.0 ± 19.6 .057 176.0 ± 25.8 .049 
Day 3 Control Run 191.4 ± 43.0 .100 159.8 ± 22.6 .324 
Day 4 Control Run 173.0 ± 10.9    .010 * 155.8 ± 31.1 .730 
Day 5 Control Run 163.6 ± 13.8 .190 158.8 ± 31.1 .522 
     
Pre - ECP Treatment Run 132.2 ± 17.4 ---- 153.4 ± 24.3 ---- 
Post - ECP Treatment Run 243.2 ± 38.3    .007 * 225.0 ± 40.9   .005 * 
Day 1 ECP Treatment Run 192.0 ± 16.2 .025 180.8 ± 19.3      .004 * 
Day 2 ECP Treatment Run 183.0 ± 26.2 .180 178.2 ± 11.3 .041 
Day 3 ECP Treatment Run 182.8 ± 24.3 .095 171.4 ± 24.4 .106 
Day 4 ECP Treatment Run 177.0 ± 25.8 .124 161.2 ± 16.8 .407 
Day 5 ECP Treatment Run 178.0 ± 24.4 .106 160.6 ± 18.7 .414 
Normal =75-190 U/L 
*Significant difference from Pre- (protected t-test, p  < .01) 
 
Creatine Kinase (CK) 
 Both males and females reached peak CK levels Day 1 post-runs (Table 16).  
Normal ranges for CK varies based on gender.  Males’ normal range is 35-232 U/L and 
females’ normal range is 21-215 U/L.  Only females experienced significantly elevated 
CK after both runs.  Though, not statistically significant, the males’ CK elevation took 
two additional days to return to normal range from the control run to the ECP treatment 
run, while the females’ CK elevation took one day less to return to normal range from the 
control run to the ECP treatment run.  The responses of both males and females to CK 
changes in this study agrees with Kyrolainen et al.
12 
who reported 4-6 days for CK to 
return to baseline levels after running a marathon.  This also agrees with Pachalis et al.
14
 
that exercise volume influences the extent of muscle damage. 
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Table 16.  Gender results for CK. 
 Males (N=5)  Females (N=5)  
Condition  Mean ± SD p-value Mean ± SD p-value 
Pre - Control Run  117.2 ±   79.8 ----    183.2 ± 124.3 ---- 
Post - Control Run 308.4 ± 130.3  .011     335.6 ± 164.6    .003 * 
Day 1 Control Run 629.6 ± 437.8 .069    520.0 ± 201.7  .019  
Day 2 Control Run 344.8 ± 180.6 .072    315.2 ± 151.6 .116 
Day 3 Control Run 193.2 ±   50.3 .112    239.8 ± 170.2 .512 
Day 4 Control Run 163.4 ±   38.5 .079    240.4 ± 236.7 .668 
Day 5 Control Run 136.8 ±   57.3 .597    212.2 ± 141.2 .756 
     
Pre - ECP Treatment Run 153.6 ± 113.9 ----       98.6 ± 37.9 ---- 
Post - ECP Treatment Run 316.4 ± 168.0    .014     223.4 ± 72.3    .003 * 
Day 1 ECP Treatment Run 675.8 ± 493.6    .071     530.0 ± 238.7    .019  
Day 2 ECP Treatment Run 388.2 ± 212.7    .048     338.4 ± 114.5    .021  
Day 3 ECP Treatment Run 307.2 ± 89.3    .033  267.4 ± 117.5    .048  
Day 4 ECP Treatment Run 258.2 ± 96.6    .049  190.4 ± 62.5    .080 
Day 5 ECP Treatment Run 230.8 ± 57.5    .205 153.4 ± 37.4   .139 
Normal = 21-215 U/L (females) 
    35-232 U/L (males) 
*Significant difference from Pre- (protected t-test, p < .01) 
 
Rinard et al.
24
 conducted research on males and females to determine whether 
responses to high-force eccentric exercises of the elbow flexors are influenced by gender.  
Males and females were found to experience significant levels of muscle soreness, 
peaking at 32 and 48 hours post-exercise, with no difference between genders.  
Thompson et al.
25
 examined the relationship between CK levels and ovulatory status in 
exercising and sedentary women.  They found that CK activity increased with exercise, in 
both ovulating groups, with the active women’s CK response being greater.  Therefore, 
degree of activity may have played a factor in levels of CK reached, as well as the5 
hormonal level.  Amenorrheic exercising women have been found to have greater CK 
elevation than sedentary and exercising normally ovulating women.
25  
Therefore, exercise 
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was the primary influence on CK levels in women with normal hormonal status.  No 
hormonal tests were administered in the current study though all female subjects reported 
no menstrual problems, irregularities, or use of birth control.  It would be beneficial to 
examine the role gender plays on the effects of ECP treatment, taking into account the 
many extraneous variables that could influence differences in gender (i.e. hormonal 
status, nutritional status, activity level, etc.).   
The current study did show differences between males and females responses 
after the control and treatment runs, therefore, hypothesis three is rejected. 
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CHAPTER V 
SUMMARY & CONCLUSION 
 
Ten trained runners ran two 20 mile runs on a pre-determined course in order to 
induce muscle soreness (experimental group—control run and ECP treatment run).  Each 
subject participated in the control run and ECP treatment run.  Trials were randomly 
counterbalanced to ensure no order effect.   
Five additional subjects underwent 5 days of ECP treatment with no exercise 
intervention (control group--ECP alone).  The purpose was to determine if ECP treatment 
alone caused muscle damage.  Muscle damage was observed by measuring biochemical 
markers of CRP, CK, and LDH.  No significant difference was noted for any of the 
markers in the control group.  It was concluded that ECP treatment alone did not cause 
muscle damage.  However, CK levels were increased; it can be argued that ECP 
treatment alone stimulates CK release while the run and other extraneous variables 
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contributed to the additional significant elevation in CK observed post-treatment as 
opposed to post-control condition. 
The experimental group experienced a 20% reduction in DOMS, as measured via 
pain scale, therefore hypothesis one was accepted.  ECP treatment reduced the delayed 
onset of muscle soreness (DOMS).  The experimental group also experienced a 40% 
reduction in CRP and a 20% reduction in LDH due to treatment.  Though treatment did 
not reduce CK elevation; CK returned to normal range one day sooner from the control 
run as opposed to the ECP treatment run.  Therefore, hypothesis two, which stated that 
ECP treatment would reduce biochemical markers of muscle damage (CRP, LDH, and 
CK), was accepted for CRP and LDH, but rejected for CK. 
Correlations were obtained to determine if relationships existed between DOMS 
and inflammation, DOMS and markers of muscle damage, inflammation and markers of 
muscle damage, and between markers of muscle damage.  All significant relationships 
were found post-control run, but none post-ECP treatment run.  Positive relationships 
were found between CRP and CK (Day 3, 4, and 5), DOMS and LDH (immediately post-
run), DOMS and CRP (Day 2), and CK and LDH (Day 5). 
To account for gender differences in biochemical markers of muscle damage and 
inflammation, analyses were run separately for each gender.  Only females experienced a 
significant difference in CRP and CK.  Females experienced a 20% increase in CRP from 
the control run to the ECP treatment run, which may be attributed to the run itself.  
Creatine kinase was significantly elevated immediately post-runs for the females, taking 
one less day to return to normal CK range from treatment.  Males, though not significant, 
took two additional days to return to normal CK range from the control run to the ECP 
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treatment run.  There was a 20% reduction in pain for both males and females due to 
treatment, though females experienced pain for one additional day.  Females experienced 
a 20% increase in LDH, which may be attributed to the run itself.  Males experienced a 
significant change Day 4 of the control run and immediately post-ECP treatment run, this 
difference between LDH significance may be attributed to the subject variability 
response.  Differences were found between genders in response to the control run and 
ECP treatment run, therefore hypothesis three was rejected.  Overall, it can be concluded 
that ECP treatment was effective in decreasing inflammation, DOMS, and LDH, but was 
not effective in decreasing CK levels.  
Application 
 The results of this study could be applied to professional and non-professional 
athletes who spend a great deal of time training, especially those who perform long 
duration eccentric exercises.  ECP treatment can aid in decreasing recovery time so that 
training can continue sooner.   
Limitations 
1. Running weather conditions varied; very cool or warm temperatures affect heart 
rate, running time, exercise performance, hydration status, and therefore DOMS.  
Subjects’ runs were scheduled within 3 to 4 weeks of each other to try and control 
for those differences. 
2. There was a subjective measurement of pain and a variation in pressure 
augmentation based on subjects’ request. 
3. A limited sample size was used in this study. 
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4. Extraneous variables: training history, muscle fiber constituents (i.e. fast to slow 
twitch fiber ratio), past experiences (i.e. injuries), hormonal status, all may 
influence enzyme activity. 
Future Research Recommendations 
1.  Based on the results of this study, and previous studies supporting ECP’s effect on 
enhancing blood perfusion to the heart, it is recommended that ECP treatment be studied 
on patients with peripheral vascular disease, such as diabetes.  Diabetics suffer from 
reduced peripheral blood flow, therefore, ECP treatment may increase peripheral blood 
flow and perfusion in diabetic patients as well. 
2.  Future research is needed to determine if a non-exercising training effect exists with 
the use ECP treatment. 
3.  Future research is needed to determine if relationships exist between CK and LDH and 
CK and CRP, since little to no research has been documented.  
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NAME _ DATE _ 
AlWACSM Prepartlclpatlon SCreening Questionnaire (AHAlACSM, 1998)1 
uaa Your Hulth Needs by Maddng All tI1Ie Statements 
Hlatory 
YOII#urot had: 
o A heart attack 
o Heart surgery 
o Cardiac catheterization 
o Coronary angioplasty (PICA) 
o Pacemaker/implantable c:azdjac 
o Defibrillator/rhytlun disturbance 
o Heart valve disease Recommendations 
o Heart failure U you marked any of the statements in this section, 
o Heart transplantation consult your healthcare provider before engaging in 
o Congenital heart disease 
Other Iwltlr issues: 
exercise. You may need to use a facility with a 
medic:ally qualified .taft. 
o You have musculoskeletal ptoblems. specify on back* 
o You have concems about the safety of ~.Specify on back* 
o You take prescription medication(s). Specify on back* 
o You are pregnant. 
Symptoms 
o You experience chest discomfort with exertion. 
o You experience unreasonable breathlessness. 
o Youexperience dizziness, fainting. blackouts. 
"IYou take heart medications. 
UJ:diovasadar risk factors 
o You are a man older than 4S years. 
o You are a woman older than 55 years or you have had a hysterectomy 
«you are postmenopausal. 
o You smoke. 
o Your blood pressure is greater than 140/90 mm Hg. 
o You don't know your blood pressure.. 
o You take blood pressure medication. 
Iiyou marked two or more of the statements in this 
section. you should consult your healthcare provider 
before engaging in exercise. You might benefit by using 
a facility with a pro.fessionally qualified exercise .taff 
o Your blood cholesterol level is > 240 mg/dl to guide your exercise program. 
o You don't know your cholesterol1eveL 
o You have a bJood relative whohad a heart attack before age 55 
(father/brother) or 65 (mother/sister). 
o You are diabetic or take medicine to control your blood sugar. 
o You are physically inactive (i.e... you get less than 30 minutes of physical 
activity on at least 3 days/weelc:). 
o You are more than 20 pounds overweight 
o None of. the above is true. You should be able to exercise safely without consultinf 
your healthcare provider in almost any faciUty that 
meets your exercise program needs. 
*	 Proceed with test if musculoskeletal problems are minor, concerns about safety of exercise 
are nonnal, and prescription medications are not for cardiac, pulmonary, or metabolic diseasE, 
_~SK STATUS(Lowi Moderate; High): 
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INFORMED CONSENT FOR PARTICIPATION
 
Effect of Counterpulsation on Delayed Onset of Muscle Soreness
 
Introduction 
You have been asked to participate in a research study to be conducted in the 
Human Performance Laboratory at Cleveland State University. It is the purpose 
of this study to measure the recovery from prolonged running with the use of 
External Counterpulsation (ECP) and its affect on reducing delayed onset of 
muscle soreness. 
Previous studies have documented changes in skeletal muscle enzymes 
resulting from the physical demands of long-distance running. Serum markers 
can be used to assess muscle damage, these include creatine kinase (CK), and 
lactate dehydrogenate (LDH). C-reactive protein is also a marker for the 
presence of inflammation. Inflammation occurs during the healing of tissue and 
may be the cause of muscle soreness after exercise. External counterpulsation 
(ECP) is a device, commonly used in cardiac patients, that increases vascular 
profusion therefore decreasing the effect of coronary artery disease. This device 
uses pneumatic pressure cuffs worn on the legs that inflate rhythmically to 
increase blood flow. Previous studies have documented that ECP increases 
myocardial blood flow in cardiac patients therefore increasing exercise tolerance. 
Procedures 
You will be asked to refrain from hard training 48 hours prior to the initial testing. 
Blood samples will be taken prior to the prolonged run and measured for CK, 
LDH, and C-reactive protein. You will then be instructed to complete a twenty 
mile run. Blood samples will be drawn immediately after the run and each day 
after until baseline levels are again achieved. 
You will complete the same run, two times. After one of the runs you will be 
treated with ECP (Approximately 45 minutes) daily until blood markers return to 
normal. The second run will be the control where only the blood markers will be 
measured and no ECP treatment will be given. 
RISKS AND DISCOMFORTS 
Risk associated with this study include mild muscle soreness resulting from the 
run. Also, discomfort experienced from giving venous blood sample. The risk 
associated with the run would be the same as experienced from your normal 
training regimen. Every effort will be made to minimize these risks. A Clinical 
Nurse SPeCialist or qualified technician will be responsible for obtaining blood 
samples and a Nurse or trained technician will be responsible for administering 
the ECP treatment. Every effort will be made to minimize these risks. 
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BENEFITS 
The benefits of this study are numerous. If ECP treatment can improve blood 
flow and reduce time for recovery during training, it would be of great importance 
for you and competitive athletes in any sport. It would also minimize muscle 
soreness associated with hard training. 
CONFIDENTIALITY 
To protect your privacy, your name will not be used in any documentation of the 
project. The information, however, may be used for a statistical or scientific 
purposes with your right of privacy retained. 
Participation 
I understand that participation in this project is voluntary and that I have the right 
to withdraw at any time with no consequences. I understand that if I have any 
questions about my rights as a participant, I can contact Cleveland State 
University's Review Board at (216)687-3630. 
I attest and verify that I have no known health problems that could prevent me 
from successfully participating in the sub-maximal graded exercise test. 
Inquiries 
Any questions about the procedures used in this project are welcome. If you 
have any doubts or questions, please ask us for further explanations or call Dr. 
Kenneth Sparks at (216) 687-4831 or Dr. Kathleen Little at (216) 687-4877. 
Patient Acknowledgement 
The procedure, purposes, known discomforts and risks, possible benefits to me 
and to others have been explained to me. I have read the consent form or it has 
been read to me, and I understand it. 
I agree to participate in this program. I have been given a copy of this consent 
form. 
Signature: Date: 
Witness: Date: 
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Pain should be reassessed at least every 24 hours 
• Key questions to ask patients 
PAIN INTENSITY - Describe the pain (sharp, aching, dull, throbbing, etc) 
LOCATION - Where on your body is the pain? 
ONSET - When did the pain start? 
DURATION - Is the pain always there or does it come and go? 
VARIATION - What makes the pain worse? 
What makes the pain better? 
QUALITY - Does the pain affect activities like sleeping, eating, 
walking, etc? 
•	 Watch for behavior, expressions, movements and activities 
that may indicate pain, eg: 
NONVERBAL - Facial wrinkltng, blinking eyes, grimacing 
INDICATORS 
- Guarding an area of the body 
- Crying, moaning 
- Decrease in soclallnteractionJroutines 
- Aggression, eg, hitttnglbiting 
- Increase in body movements 
- Irritability; incre~sed confusion 
Pain Assessment Scales 
No Distressing Unbearable 
pain pain pain 
I I I I I' l 
o 2 3 4 5 6 7 8 9 10 
rIO'" 1><0> A. C,.. De, P" .. R. Ol.t. ClIokll Pllelir. C...... N•• '}, .....,.111c."" PwIJl. Rockville, Md: US Depl 01 He.lth .nd H..... 50"'1<0'....."C)' "" 1le.I,h 
~ Pohcy ond R....""', I~, AHCPIl publlcotlon 94-0~1 
@@
 
o 2 4 6 [I. 10 
NoHul1 Hurts little 8it Hurts Little More Hurts Even More Hurls Whole LOI Hurts Worst 
®..... 00 '..::::/ 
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